Literature DB >> 27526054

Spinal Cord Stimulation for Intractable Testicular Pain: Case Report and Review of the Literature.

Michael P Kiritsy1, Jason W Siefferman1.   

Abstract

OBJECTIVE: Treating chronic testicular pain is often challenging, and few treatment options have been reported. We report a case of intractable testicular pain successfully treated with spinal cord stimulation (SCS). CASE: A 59-year-old male with a 40-year history of bilateral testicular pain after ruptured epididymitis presented for consultation after failing multiple medical and surgical treatments. Repeat genitofemoral nerve block gave him temporary relief. SCS trial to target this distribution resulted in complete pain relief, and the patient was referred for implantation. He reported continued relief nine months after implantation. DISCUSSION: This is the third reported case of intractable chronic testicular pain successfully treated with SCS. Although evidence is scarce, SCS appears to be a potential treatment for patients with testicular pain presenting with a clear distribution of pain.
© 2016 International Neuromodulation Society.

Entities:  

Keywords:  case report; chronic pain; neurostimulation; pelvic pain; spinal cord stimulation

Mesh:

Year:  2016        PMID: 27526054     DOI: 10.1111/ner.12487

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  3 in total

1.  Evaluation and Management of Chronic Scrotal Content Pain-A Common Yet Poorly Understood Condition.

Authors:  Matthew J Ziegelmann; M Ryan Farrell; Laurence A Levine
Journal:  Rev Urol       Date:  2019

Review 2.  Chronic Scrotal Content Pain: a Review of the Literature and Management Schemes.

Authors:  Paul J Oh; Petar Bajic; Scott D Lundy; Matthew Ziegelmann; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2021-01-15       Impact factor: 3.092

Review 3.  Chronic Testicular and Groin Pain: Pathway to Relief.

Authors:  Nahomy Calixte; Jamin Brahmbhatt; Sijo Parekattil
Journal:  Curr Urol Rep       Date:  2017-09-02       Impact factor: 3.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.